Transgene Biotek Limited (BOM:526139)

India · Delayed Price · Currency is INR

2.760

+0.050 (1.85%)

At close: Sep 16, 2026

Market Cap	205.34M -28.3%
Revenue (ttm)	2.22M -15.1%
Net Income	-16.08M
EPS	-0.21
Shares Out	75.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,397
Open	2.720
Previous Close	2.710
Day's Range	2.690 - 2.830
52-Week Range	1.830 - 4.500
Beta	0.97
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Transgene Biotek

Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. T... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1990

Country India

Stock Exchange Bombay Stock Exchange

Ticker Symbol 526139

Full Company Profile

Financial Performance

In fiscal year 2026, Transgene Biotek's revenue was 2.11 million, a decrease of -18.99% compared to the previous year's 2.61 million. Losses were -16.53 million, 144.5% more than in 2025.

Financial Statements